CD80 and CD86 as Survival Markers in Nasopharyngeal Carcinoma
Author Information
Author(s): Chang Cheng-Shyong, Chang Julia H, Hsu Nicholas C, Lin Hsuan-Yu, Chung Chih-Yuan
Primary Institution: Changhua Christian Hospital, Changhua, Taiwan
Hypothesis
The expression of CD80 and CD86 costimulatory molecules is associated with better survival outcomes in patients with nasopharyngeal carcinoma.
Conclusion
The expression of CD80 and CD86 costimulatory molecules appears to be a marker of better survival in patients with nasopharyngeal carcinoma.
Supporting Evidence
- CD80 and CD86 were expressed in 10 of 50 cases, with co-expression in 9 cases.
- Patients with CD80/CD86 expression had significantly better overall survival than those without it.
- The study suggests that the presence of B7 costimulatory molecules may influence survival outcomes.
Takeaway
This study found that patients with certain markers in their tumors might live longer, but more research is needed to be sure.
Methodology
The study examined tissue samples from newly diagnosed nasopharyngeal carcinoma patients for the expression of CD80, CD86, and other markers using immunohistochemical techniques.
Potential Biases
Potential investigator bias was minimized by having two independent pathologists score the samples.
Limitations
The study had a small sample size, which limits the ability to draw strong conclusions.
Participant Demographics
The study included 50 newly diagnosed nasopharyngeal carcinoma patients, with a median age of 50 years.
Statistical Information
P-Value
0.017
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website